Golidocitinib Versus Placebo as Maintenance Therapy in Peripheral T-Cell Lymphoma Patients With Response (CR/PR) After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial
Latest Information Update: 27 Feb 2026
At a glance
- Drugs Golidocitinib (Primary)
- Indications Follicular lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 27 Feb 2026 New trial record